Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention provides a system for detecting the removal of an item or items from a secure area. The system includes a secure area in which the item or items are located, one or more entrances to and/or exits from the secure area, one or more items, those items provided to be formed of a plastics or other polymeric material, and the item or items further including a plurality of metal detectable particles and/or X-ray detectable material embedded within the plastics material. Detection or sensor apparatus are provided to be located at the one or more entrances to and/or exits of the secure area, arranged to detect or sense the passage of metal detectable particles and/or X-ray detectable material therethrough, in use.

Abstract: The present disclosure relates to a hybrid continuous positive pressure and surface imaging system for use in a radiotherapy system, including: a positive pressure unit adapted to apply a continuous positive pressure to lungs of a patient during radiotherapy; a surface camera system configured to continuously, or at intervals, capture body surface images of the patient; and a processing unit configured to continuously, or at intervals, model chest and/or abdominal movement of the patient in response to the applied continuous positive pressure based on the body surface images. The disclosure further relates to a computer-implemented method of providing real-time feedback to a positive pressure unit.

Abstract: Disclosed herein are substituted quinoxalines, methods for their preparation, and use thereof.

Abstract: An electronics device provided for a drug delivery device or a drug delivery add-on device is disclosed, wherein the drug delivery device or the drug delivery add-on device comprises a dose measurement function and a data transmission function. The electronics device comprises at least one first controller unit being provided for controlling dose related functions of the drug delivery device or drug delivery add-on device and for data processing functions comprising one or more first numerical calculations with dose related data, and at least one second controller unit being provided for data processing functions comprising one or more second numerical calculations with dose related data having a higher complexity than the first numerical calculations and communication functions, wherein the at least one first controller unit is designed for using less power than the at least one second controller unit.

Abstract: The present invention relates to an electronic system (100) for a drug delivery device (1), in which a first member (20) performs a specific movement relative to a second member (11) during a dosing operation. The electronic system (100) comprises a sensor arrangement (120), which is operable to provide sensor data describing the specific movement and is configured to operate the sensor arrangement (120) during at least one part of the dosing operation to provide sensor data. In order to protect the users from relying on incorrectly measured dose sizes and a need to reduce the risk that an injection is painful for the patient, the electronic system (100) is configured to determine, based on the sensor data, if a speed of the specific movement during the at least one part of the dosing operation breaches a first speed threshold.

Abstract: Measurement system for a drug delivery device, drug delivery device with such a measurement system and method for measuring the dose dispensed and/or dose set of a drug delivery device. Proposed is a measurement system for a drug delivery device, a drug delivery device comprising such a system and a related method, the measurement system comprising—a dose control member configured to move in accordance with a dose dispense operation and/or a dose set operation, e.g.

Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: An electronic system for a drug delivery device comprises a dose setting and drive mechanism, which is configured to perform a dose setting operation and a dose delivery operation for delivering a set dose. The electronic system comprises a sensor arrangement for generating measurement data related to a size of the dose set by the dose setting operation and/or delivered by the dose delivery operation, a microcontroller system connected to the sensor arrangement, the microcontroller system comprising at least one microcontroller, and a memory. The microcontroller system operates the sensor arrangement during the dose setting operation and/or during the dose delivery operation and stores a dose record in the memory. For providing data regarding dose delivery operations in an easy, flexible and yet reliable and energy-efficient manner, the microcontroller system is configured to set at least one flag and/or a specific purpose value in the dose record under pre-defined circumstances.

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: A grill rack system includes at least one grill rack, a left-hand grill bracket, and a right-hand grill bracket. In one embodiment, the grill brackets each include only one set bolt. In an alternative embodiment, each of the grill brackets includes at least one rack track guide defining a rack track guide opening. In an alternative embodiment, the grill rack includes at least one rear crossmember alignment tab. The grill brackets each include at least one rack track guide each defining rack track guide opening and each including the at least one alignment tab disposed in the at least one rack track guide.

Abstract: Disclosed herein are crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile free base, pharmaceutically acceptable compositions comprising these crystalline forms, and methods for using these crystalline forms.

Abstract: The present invention relates to compounds that inhibit KRas G12C; in particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: A server performs a method for automatically provisioning an electronic device installed at an installation location. The server receives (e.g., from a mobile application) information relating to installation of the electronic device at the installation location. The installation information includes at least one image captured at the installation location. The server determines whether location information for the electronic device was received from the electronic device after the device was installed. Responsive to determining that location information for the electronic device was not so received, the server determines whether the at least one image includes geolocation metadata. When the at least one image includes geolocation metadata, the server determines the geolocation of the electronic device based on the geolocation metadata.

Abstract: A mobile device, such as a smartphone, tablet computer, or other handheld electronic device, includes a display, a camera, a memory, and a processor. The memory may store operating instructions for the processor. Such operating instructions may be in the form of preinstalled operating system software or firmware, or a downloaded mobile application. The mobile device processor is operable in accordance with the operating instructions to determine whether the mobile device has moved repeatedly (e.g., has been shaken) within a motion detection time period and, if so, activate the camera; present on the display a live image stream captured by the camera; start a timer to count down time for a countdown time period; upon expiration of the countdown time period, automatically control the camera to capture an image from the live image stream; and store an image file including the captured image in the memory.

Abstract: Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.

Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The invention to which this application relates to improvements to a retaining band which can be used to securely locate, form and retain a load of items or goods, in one embodiment on a pallet, and thereby retain the said items or goods as a single integral package. The invention allows for the adaptation of the retaining bands to be detectable when with a predetermined range of detection apparatus such as X-ray and/or metal detection apparatus so that should the retaining band or fragments thereof be discarded or dislodged, the presence of the same is detectable and therefore prevented from becoming a potential contaminant or safety hazard.

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.